On March 31, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, reported a business update highlighting the Company’s accelerating transition toward clinical development and a series of upcoming milestones expected to serve as key value-inflection points over the next 12-18 months.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Following significant scientific, regulatory and operational progress, Ernexa is entering a pivotal execution phase as it advances its lead program, ERNA-101, toward a first-in-human clinical trial expected to begin in Q4 2026 for the treatment of platinum-resistant ovarian cancer. The Company is currently completing the final steps required to support an Investigational New Drug (IND) submission in Q3 2026.
ERNA-101 is an engineered synthetic induced-mesenchymal stem cell (iMSC) therapy designed to deliver immune-activating cytokines directly to the tumor microenvironment, with the goal of converting immunologically "cold" tumors into immune-responsive tumors. Recent preclinical data further strengthen the rationale for ERNA-101 as a potential treatment for ovarian cancer. In a syngeneic ovarian cancer model, the combination of an anti-PD-1 mAb plus ERNA-101 demonstrated durable antitumor activity, including high rates of complete tumor regressions, significantly prolonged survival. When combined with PD-1 blockade, ERNA-101 produced markedly enhanced responses compared with either agent alone, supporting its potential to convert immunologically "cold" tumors into responsive tumors and reinforcing the Company’s confidence as the program advances toward first-in-human clinical studies.
Key Highlights
Combination drives high rates of complete tumor regressions and significantly extended survival in aggressive ovarian cancer model, supporting ERNA-101 as a potential foundational immunotherapy platform
Company on track to commence first-in-human clinical trials of ERNA-101 in ovarian cancer in Q4 2026
"The coming year represents a transformative period for Ernexa as we transition from a preclinical organization into a clinical-stage biotechnology company," commented Sanjeev Luther, President and CEO of Ernexa Therapeutics. "With an IND submission for ERNA-101 and our first-in-human study anticipated this year, we are approaching multiple important inflection points that we believe can unlock significant value while advancing a novel cell therapy platform designed to address cancers and autoimmune diseases with high unmet medical need."
In parallel with the advancement of ERNA-101, Ernexa continues to develop ERNA-201, an engineered anti-inflammatory iMSC therapy designed to deliver IL-10 directly to inflamed tissues for the treatment of autoimmune diseases, including rheumatoid arthritis.
Recent Achievements
2025 – Completed
Streamlined operations to reduce general and administrative expenses by approximately 61% year over year, while maintaining focus on advancing core programs
Completed Proof of Principle (PoP) studies for ERNA-101 and ERNA-201
Successfully completed Pre-IND meeting with the FDA for ERNA-101
Near-Term Milestones Expected to Drive Value
Ernexa expects the following operational, regulatory and clinical milestones to serve as key catalysts as the Company advances toward clinical development. Supported by a recent $10.5 million financing, the Company is well-positioned to achieve several key value inflection points.
Upcoming Milestones
Q2/Q3 2026: Completion of ERNA-101 clinical manufacturing process development in Q2 2026, followed by release of the first product batch in Q3 2026
Q3 2026: Completion of required IND-enabling preclinical studies for ERNA-101
Q3 2026: Submission of Investigational New Drug (IND) application for ERNA-101
Q4 2026: Initiation of first-in-human Phase 1 clinical study of ERNA-101 for treatment of platinum-resistant ovarian cancer
Q4 2026: Pre-IND meeting with the FDA for ERNA-201
1H 2027: Initial clinical data readout from ERNA-101
2H 2027: Advancement into Phase 2 trials with a potential co-development partner
Continue to present data at upcoming leading scientific conferences
"These upcoming milestones represent a clear pathway toward clinical validation of our platform and the potential expansion of our programs into broader oncology and autoimmune indications," Luther added. "We believe our engineered iMSC platform has the potential to deliver targeted cytokine therapies directly to sites of disease, opening the door to a new class of cell-based therapeutics."
(Press release, Ernexa Therapeutics, MAR 31, 2026, View Source [SID1234664102])